InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Progress on Phase 3 Psychedelic Therapeutics Program
June 13, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) issued a corporate update emphasizing continued momentum in its clinical pipeline, including the advancement of its lead candidate CYB003 into Phase 3 development. CEO Doug Drysdale underscored the growing regulatory clarity around psychedelic therapeutics and expressed optimism that Cybin’s IP portfolio and clinical strategy position the company to help […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at H.C. Wainwright Neuro Perspectives Conference
June 12, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that Chief Executive Officer Doug Drysdale will participate in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Conference, scheduled for June 16–17, 2025. The company is advancing next-generation neuropsychiatric treatments aimed at transforming mental healthcare. To view the full press release, visit https://ibn.fm/BjhYH About […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak on Pivotal Trials Panel at Psychedelic Science 2025
June 11, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will speak at the Psychedelic Science 2025 Conference, held June 16–20 in Denver. Drysdale will participate in the panel “The Home Stretch: Pivotal Trials and Preparing for Launch” on Thursday, June 19 at 9:30 a.m. MDT. He emphasized the importance of collaborative dialogue in […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB004 Anxiety Treatment Candidate
June 3, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company focused on next-generation mental health therapies, announced the issuance of U.S. patent 12,318,477 supporting its CYB004 program, a deuterated DMT candidate being developed for generalized anxiety disorder (“GAD”). The patent, which covers novel intramuscular formulations of DMT and related compounds, extends exclusivity through 2040. CEO […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Discuss Phase 3 Progress and Industry Trends in May 29 Fireside Chat
May 22, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will join a Water Tower Research Fireside Chat on May 29, 2025, at 11 a.m. ET. The discussion will cover Cybin’s CYB003 Phase 3 program, recent clinical partnerships, its collaboration with Thermo Fisher, and insights on the evolving regulatory landscape for psychedelics. The event […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Applauds FDA Support for Psychedelic Therapeutics, Advances Phase 3 Trials
May 20, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) welcomed recent comments from FDA Commissioner Dr. Martin Makary endorsing the accelerated development of psychedelic therapeutics. The company, which is conducting Phase 3 trials of CYB003 for major depressive disorder (MDD) and Phase 2 trials of CYB004 for generalized anxiety disorder (GAD), said the FDA’s openness validates its mission […]
Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform
May 19, 2025
Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans—a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Taps Thermo Fisher for Phase 3 and Commercial Production of CYB003
May 15, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) has partnered with Thermo Fisher Scientific to support Phase 3 clinical supply and potential commercial manufacturing of CYB003, its proprietary deuterated psilocin treatment for major depressive disorder (MDD). The agreement expands on Cybin’s existing U.S.-based manufacturing operations, with Thermo Fisher handling drug substance in South Carolina and capsule production […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Alliance Global Partners Healthcare Showcase on May 21
May 14, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase on May 21, 2025. The session will be webcast live at 1:40 p.m. ET and later available via the company’s investor relations site. To view the full press release, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB003 Depression Treatment
May 8, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company, announced the issuance of U.S. patent 12,291,499 for its CYB003 program targeting major depressive disorder (MDD). The patent covers pharmaceutical compositions and oral dosage forms related to Cybin’s proprietary deuterated psilocin analog and offers exclusivity through 2041. The company is currently dosing patients in a Phase […]
NECANN Cannadelic Miami 2025 to Ignite Miami’s Wellness Evolution
May 6, 2025
Researchers, scholars, wellness seekers, and industry experts are invited to attend the NECANN Cannadelic Miami 2025, held at the Miami Airport Convention Center, Miami, FL, from May 23 to 24, 2025. This transformative two-day event empowers attendees to explore the frontiers of emerging therapies, plant-based medicine, and next-gen healing. Based on the inspiring theme “Elevate […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at Milken Global Conference on Medical Breakthroughs
May 1, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will speak at the 28th Annual Milken Institute Global Conference on May 5 at 2:30 p.m. PDT. He will join the panel “The Global Landscape and Opportunities for Medical Breakthroughs” to discuss innovation in drug development and next-generation mental health treatments. The event will […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Phase 3 Trial Network to 18 Sites for CYB003 in Depression
April 23, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced the expansion of its strategic partnership agreements to include 18 U.S. clinical sites for its multinational Phase 3 trial of CYB003, a next-generation psychedelic-based therapy for major depressive disorder (MDD). The APPROACH study, part of Cybin’s PARADIGM program, is expected to grow to approximately 45 sites. By leveraging […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Forms Strategic Partnership With Osmind to Prepare for Mental Health Drug Commercialization
April 21, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company, has entered a strategic partnership with Osmind, a technology and services provider with a network of over 800 U.S. psychiatry clinics. The collaboration aims to lay the groundwork for the commercialization of Cybin’s clinical programs CYB003, in Phase 3 for major depressive disorder, and CYB004, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Q3 Financials, Advances Clinical Programs
February 11, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced third-quarter financial results and recent developments in its neuropsychiatry pipeline. The company continues advancing its lead programs, including CYB003, which has entered a multinational Phase 3 trial for major depressive disorder, and CYB004, now in Phase 2 testing for generalized anxiety disorder. Financially, Cybin reported a net loss of […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Launches Strategic Partnership Program with Segal Trials for Phase 3 MDD Study
January 15, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a neuropsychiatry platform company, announced its first strategic partnership agreement (“SPA”) with Segal Trials as part of its multinational pivotal Phase 3 program for CYB003, targeting Major Depressive Disorder (“MDD”). Segal Trials, a South Florida-based research network specializing in psychiatry and psychedelics, joins Cybin in advancing its Phase 3 […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights 2024 Achievements and Outlines Key 2025 Milestones
January 13, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company, summarized its 2024 accomplishments and detailed upcoming 2025 milestones. CEO Doug Drysdale highlighted advancements in its pipeline of tryptamine serotonin receptor agonists, including CYB003, a deuterated psilocin program for major depressive disorder (“MDD”), and CYB004, a deuterated dimethyltryptamine in intramuscular form for generalized anxiety disorder […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Lytham Partners Healthcare Summit
January 10, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company, announced that CEO Doug Drysdale will join a fireside chat at the virtual Lytham Partners 2025 Investor Healthcare Summit on Jan. 13. The live webcast begins at 11:30 a.m. ET, with an archived version accessible afterward on the company’s investor relations site. To view the […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Promising Advances in Depression and Anxiety Treatment at ACNP Annual Meeting
December 10, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) presented compelling data from its clinical programs at the American College of Neuropsychopharmacology (“ACNP”) Annual Meeting, including 12-month efficacy results from its Phase 2 study of CYB003, a deuterated psilocin program for Major Depressive Disorder (“MDD”), which demonstrated a 100% response rate and 71% remission rate after two doses. […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Water Tower Research Fireside Chat
December 4, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options. The company has announced that its CEO Doug Drysdale and CMO Amir Inamdar, MBBS, DNB (Psych), FFPM will participate in the Water Tower Research Fireside Chat Series taking place […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Sustained 12-Month Efficacy for CYB003 in Treating Major Depressive Disorder
November 18, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) shared promising 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin treatment for major depressive disorder (“MDD”). Participants receiving two 16 mg doses of CYB003, three weeks apart, achieved a 100% response rate and 71% remission rate at the 12-month mark, with an average […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present Key 12-Month Data and Phase 3 Program Insights for CYB003 in Upcoming Webcast
November 14, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) announced it will hold a conference call and webcast on Nov. 18, 2024, at 8 a.m. ET, led by CEO Doug Drysdale and CMO Amir Inamdar. The event will cover 12-month efficacy and safety results from its Phase 2 study of CYB003 for Major Depressive Disorder, along with an […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Begins Phase 3 Trials of CYB003 for Depression, Building on Promising Phase 2 Results
November 13, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) has initiated its Phase 3 PARADIGM program to evaluate the efficacy and safety of CYB003, an adjunctive treatment for Major Depressive Disorder (MDD). PARADIGM includes three pivotal studies: APPROACH, EMBRACE, and EXTEND, each aimed at examining CYB003’s potential to deliver rapid and durable relief from depressive symptoms. In Phase 2, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present Advancements in Mental Health Treatment at Milken Institute Summit
October 31, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will join a panel titled “The Next Frontier in Mental Health Research” at the 2024 Milken Institute Future of Health Summit in Washington, D.C., on November 13. Drysdale will discuss Cybin’s progress in developing breakthrough treatments for mental health conditions, including CYB003, a Phase […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Granted Patent for Lead Candidates in CYB005 Program
October 24, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that the United States Patent and Trademark Office has granted U.S. patent 12,122,741 for the composition of matter related to lead preclinical candidates in its CYB005 phenethylamines program. This patent supports Cybin’s development of non-hallucinogenic treatments for Central Nervous System (“CNS”) disorders. Cybin is focused on expanding its […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in Upcoming Water Tower Research Fireside Chat
October 3, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the Water Tower Research Fireside Chat Series on Tuesday, October 8, 2024, at 3 p.m. ET. Cybin CEO Doug Drysdale will join the fireside chat hosted by Robert Sassoon, Senior Research Analyst […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Strengthens Its Clinical Development Team
October 1, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced the appointment of talented and experienced industry leaders to its clinical and R&D team. The company welcomed Dr. Mirza Rahman, M.D., M.P.H., FACPM, as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Chief Medical Officer to Participate in a Panel Discussion at Upcoming Summit
September 24, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced that it will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit to be held virtually on Thursday, September 26, 2024. The company’s Chief Medical Officer, Amir Inamdar, will be part […]
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Subsidiary Signs Agreement with Evofem Biosciences Inc. (OTCQB: EVFM) Involving Unique Endometriosis Diagnostic Test
September 20, 2024
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and its majority-owned subsidiary, Pearsanta Inc., have signed a market development collaboration agreement with Evofem Biosciences (OTCQB: EVFM), a women’s health company. According to the announcement, the agreement involves Pearsanta’s blood-based diagnostic test for endometriosis, which affects an estimated 190 million women globally. The […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports on Status of Key Clinical Milestones
September 20, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, has provided an update on corporate accomplishments and clinical milestones. According to the announcement, the company is planning to begin a pivotal CYB003 phase 3 study in major depressive disorder (“MDD”) […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Completes 38-for-1 Share Consolidation
September 19, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced that it has completed the previously announced consolidation of its issued and outstanding common shares. Trading of the common shares reflecting the consolidation commenced at the opening of trading on Thursday morning. According to […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options. The company today announced that its CEO, Doug Drysdale, will participate in a fireside chat and panel discussion at the H.C. Wainwright 26th Annual Global Investment Conference. The event will be held September 9-11, 2024, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Annual and Special Meeting of Shareholders, Share Consolidation
August 28, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is releasing the report of its annual and special meeting of shareholders. Held on Aug. 27, 2024, the meeting included 87 shareholders, attending in person or by proxy; those persons […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Holds Initial Breakthrough Therapy Meeting with FDA, Plans for CYB003 Phase 3 Trial
August 13, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, met with the U.S. Food and Drug Administration (“FDA”) to hold a Type B Initial Breakthrough Therapy Meeting. The meeting, which was held last week, was regarding the company’s plans […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases Q1 2025 Financial Results, Business Highlights
August 8, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today reported unaudited financial results for its first quarter of fiscal 2025 ended June 30, 2024 (“Q1 2025”) and provided recent business highlights. In the report, the company noted continued progress towards initiating its Phase 3 […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in a Fireside Chat at Upcoming Conference
August 7, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced that its CEO, Doug Drysdale, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024, at 2 p.m. ET. Mr. Drysdale’s fireside chat will be […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Sees “Swell” of Insider Investments, Upgrade in Ranking after Positive Year-End Report
July 8, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting “a swell” of insider purchases following the company’s year-end update; the report highlighted significant advancements that strengthened Cybin’s position in the development of next-generation psychedelic-based therapeutics. […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases FY Financial Report, Business Update
June 26, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting its audited financial results for the fiscal year ended March 31, 2024; the report also included a business overview. Highlights of the report include the company […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Featured Presenter at Upcoming H.C. Wainwright Neuro Perspectives Virtual Conference
June 20, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be spotlighted during an upcoming online fireside chat at the H.C. Wainwright Fifth Annual Neuro Perspectives Virtual Conference. According to the announcement, Cybin CEO Doug Drysdale will present during […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Strategic Appointment of Dr. Atul Mahableshwarkar
June 11, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company today announced its appointment of Dr. Atul R. Mahableshwarkar M.D., DLFAPA, as its senior vice president, clinical development. Dr. Mahableshwarkar will lead the development of the CYB003 […]